---
title: "Rafael Holdings reports Q2 fiscal 2025 results; merger with Cyclo Therapeutics set to close in Q3 pending approvals."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/231757810.md"
description: "The merger with Cyclo Therapeutics is expected to be completed in the third quarter, subject to approval from shareholders."
datetime: "2025-03-13T22:12:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/231757810.md)
  - [en](https://longbridge.com/en/news/231757810.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/231757810.md)
generator: "portal-rs"
---

# Rafael Holdings reports Q2 fiscal 2025 results; merger with Cyclo Therapeutics set to close in Q3 pending approvals.

The merger with Cyclo Therapeutics is expected to be completed in the third quarter, subject to approval from shareholders.

### Related Stocks

- [CYTH.US](https://longbridge.com/en/quote/CYTH.US.md)

## Related News & Research

- [Zepp Health Non-GAAP EPADS of -$0.79, revenue of $63.53M; gives Q3 outlook](https://longbridge.com/en/news/297733174.md)
- [Defence Therapeutics completes $9.6 million private placement at $0.55 per unit](https://longbridge.com/en/news/298138132.md)
- [Braidwell LP Invests $34.02 Million in Maze Therapeutics, Inc. $MAZE](https://longbridge.com/en/news/297882633.md)
- [Damora Therapeutics grants new hires options for 135,400 shares at $28.18 each](https://longbridge.com/en/news/297910210.md)
- [Jason Coloma Sells 34,501 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock](https://longbridge.com/en/news/298024574.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**